Lidocain-Egis (Lidocaine Hydrochloride)

Lidocain-Egis, a local anesthetic acting on voltage‑gated sodium channels, is indicated for the following clinical situations:

• Minor surgical procedures: provides rapid, reversible loss of sensation to facilitate pain‑free operation.
• Diagnostic procedures: enables comfortable performance of endoscopic or catheter‑based examinations.
• Ventricular arrhythmias: stabilizes cardiac electrical activity to suppress life‑threatening rhythm disturbances.

• Lidocaine hydrochloride exerts its effect by binding to the intracellular portion of voltage‑gated sodium channels in neuronal and cardiac membranes. This blockade prevents the rapid influx of sodium ions during the depolarization phase, thereby inhibiting the initiation and propagation of action potentials. In cardiac tissue, the reduced excitability diminishes abnormal automaticity and re‑entry circuits, while in peripheral nerves it produces a reversible loss of sensory and motor conduction.

Lidocain-Egis may be associated with adverse reactions that vary in frequency and severity.

Common Side Effects

• Tingling or numbness at the injection site.
• Transient dizziness or light‑headedness.
• Mild hypotension.

Serious or Rare Side Effects

• Anaphylaxis with rash, bronchospasm or angioedema.
• Cardiac conduction disturbances such as bradycardia or heart block.
• Central nervous system toxicity, including seizures.

When using Lidocain-Egis, clinicians should observe specific precautions to minimize risk.

• Patient assessment: evaluate cardiac history and existing conduction abnormalities before administration.
• Dose titration: adjust dosage based on age, weight and hepatic function, especially in elderly patients.
• Monitoring: continuously monitor ECG and blood pressure during intravenous infusion.
• Drug interactions: avoid concurrent use with other class I anti‑arrhythmics or potent CYP450 inhibitors without supervision.
• Allergic history: confirm no prior hypersensitivity to amide‑type local anesthetics.
• Store at ambient temperature: keep the solution below 25 °C, protect from light, and retain in original packaging.

Lidocain-Egis can interact with several medicines that affect its plasma levels or cardiac effects.

Major Interactions (Avoid)

• Class I anti‑arrhythmic agents (e.g., quinidine, procainamide) – additive cardiotoxicity.
• Beta‑blockers (e.g., propranolol) – enhanced bradycardia and hypotension.
• CYP3A4 inhibitors (e.g., ketoconazole) – increased lidocaine concentrations.

Moderate Interactions (Monitor Closely)

• CYP1A2 inducers (e.g., carbamazepine) – reduced efficacy.
• Diuretics (e.g., furosemide) – may potentiate hypotensive effects.
• General anesthetics (e.g., propofol) – may require dosage adjustment.